 |
|
|
 |
Infliximab to Etanercept Switch in Patients with Spondyloarthropathies and Psoriatic Arthritis: Preliminary Data
CAROLINE DELAUNAY, VALÉRIE FARRENQ, ANDRÉ MARINI-PORTUGAL, JEAN-DAVID COHEN, XAVIER CHEVALIER, and PASCAL CLAUDEPIERRE
ABSTRACT.
Objective. To report early experience of switching anti-tumor necrosis factor-a (TNF-a) therapy from infliximab to etanercept in patients with spondyloarthropathy (SpA) and psoriatic arthritis (PsA). Methods. Thirteen patients with various SpA (7 with ankylosing spondylitis and 6 with undifferentiated SpA) and 2 patients with PsA were receiving infliximab. Because they were experiencing inadequate response or adverse events, therapy was changed to etanercept. Patients were evaluated for response to the change in anti-TNF-a therapy at baseline, after 3 months, and then every 6 months. Results. During the mean 10-month followup after the change in therapy, 9 of 13 patients with SpA and both patients with PsA responded to etanercept and none experienced intolerance to this agent. Conclusion. These data suggest that switching between anti-TNF-a drugs may be useful for patients with SpA who are unresponsive or intolerant to a first anti-TNF-a agent. (J Rheumatol 2005;32:2183-5) Key Indexing Terms:
SPONDYLOARTHROPATHY
From the Department of Rheumatology, Henri Mondor Teaching Hospital, Créteil, France. C. Delaunay, MD; V. Farrenq, MD; A. Marini-Portugal, MD; J-D. Cohen, MD; X. Chevalier, MD, PhD; P. Claudepierre, MD. Address reprint requests to Dr. P. Claudepierre, Service de Rhumatologie, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil Cédex, France. E-mail: pascal.claudepierre@hmn.ap-hop-paris.fr Accepted for publication June 27, 2005. |